Oruka Therapeutics (ORKA) AI Stock Analysis

• Market Cap: $2.02B
• Dividend Yield: N/A
• Average Volume (3M): 530.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: N/A
• EPS Growth: 63.85%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 49,542,690
• 10 Day Avg. Volume: 602,310
• 30 Day Avg. Volume: 530,527
• PEG Ratio: 0.24
• Price to Book (P/B): 2.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -15.64
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -50.32K
• Enterprise Value/Ebitda: -12.78
• 1Y Price Target: $61.50
• Price Target Upside: 50.74% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): -2.55
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $41.00 ▲(0.49% Upside)
• Action: Reiterated Date: 03/14/26
• Date: Action: Reiterated 03/14/26

The score is held back primarily by weak financial performance (no revenue, rising losses, and accelerating cash burn), partially offset by a strong solvency profile and favorable technical momentum. Valuation remains difficult to support due to negative earnings and no dividend data.

Positive Factors

Solvency / Balance Sheet

Very low leverage and a growing equity base provide durable solvency and financial optionality for a clinical-stage biotech. This reduces near-term refinancing risk, supports ongoing trial funding and partnership negotiations, and preserves strategic flexibility versus highly leveraged peers.

Favorable Pharmacology / Dosing Profile

A long half-life enabling infrequent dosing is a structural product advantage: it can improve adherence, lower total treatment burden and costs, and differentiate the asset in psoriasis and hidradenitis suppurativa markets, enhancing commercial and partnership appeal long term.

Advancing Clinical Programs

Progressing co-lead programs and completed enrollment materially de-risks some development milestones. Consistent trial advancement builds clinical validation, increases chances of partnering or licensing, and creates tangible near-to-medium term value inflection points for the pipeline.

Negative Factors

No Revenue / Widening Losses

The company remains pre-revenue with materially expanding operating losses, a structural challenge for sustainability. Continued negative earnings consume equity, reduce return on invested capital, and increase reliance on external funding until successful commercialization or strategic partnering occurs.

Accelerating Cash Burn

Steeply increasing operating and free cash outflows create a durable financing requirement. Absent product revenue or major milestones that trigger partner payments, accelerating burn raises the probability of further capital raises and constrains long-term R&D pacing and strategy.

Dependence on External Financing

Reliance on equity financings to fund operations is structural for the company. While the PIPE extends runway, it signals continued dilution risk and the likelihood of future raises if trials or partnerships do not generate revenues or material upfront payments.

Oruka Therapeutics Business Overview & Revenue Model

Company Description

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

How the Company Makes Money

As a clinical-stage biotechnology company, Oruka Therapeutics does not have publicly available evidence of recurring product revenue from marketed therapies; as such, revenue from commercial drug sales is null. The company primarily funds operations through external financing (e.g., equity offerings and other capital-raising activities). Any additional revenue streams such as upfront payments, milestones, royalties, or R&D service income from licensing and partnerships are null unless specifically disclosed in the company’s public filings; significant partnerships contributing to earnings are null based on unavailable information in this context.

Oruka Therapeutics Financial Statement Overview

Summary

Balance sheet strength (very low leverage and a sizable, growing equity base) supports solvency, but overall financial performance is constrained by zero revenue, widening operating losses, and accelerating cash burn that increases future financing risk.

Income Statement

The company has generated no revenue across the provided years, while losses have expanded materially (net loss of ~$83.7M in 2024 to ~$105.4M in 2025). Operating losses are substantial and widening (EBIT of about -$88.1M to -$122.1M), consistent with a development-stage biotech spending heavily on R&D. Strength is that the cost structure is clearly geared toward investment, but the lack of revenue and growing losses keep profitability and visibility weak.

Balance Sheet

The balance sheet looks strong from a solvency standpoint: leverage is very low (debt-to-equity ~0.3%–0.4% in 2024–2025) and equity is sizable and growing (about $382.2M in 2024 to $471.9M in 2025), supporting a solid asset base (~$488.6M in 2025). The key weakness is negative returns on equity (roughly -22% in 2024–2025) driven by ongoing losses, implying the capital base is being consumed rather than earning returns.

Cash Flow

Cash burn is significant and accelerating: operating cash flow declined from about -$57.8M (2024) to -$88.2M (2025), with free cash flow similarly negative (about -$58.0M to -$88.4M). A positive note is that cash outflow broadly tracks reported losses (free cash flow roughly in line with net loss), suggesting limited non-cash distortion, but the overall trajectory points to increasing funding needs if revenue does not materialize.

Breakdown	Dec 2025	Dec 2024	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-83.00K	-27.00K	-114.00K	-91.00K	-93.00K
EBITDA	-121.97M	-82.23M	-9.81M	-19.23M	-9.64M
Net Income	-105.43M	-83.72M	-9.93M	-19.32M	-9.74M
Balance Sheet
Total Assets	488.62M	396.02M	43.09M	54.92M	50.43M
Cash, Cash Equivalents and Short-Term Investments	337.04M	375.65M	42.45M	53.36M	49.07M
Total Debt	1.93M	968.00K	383.00K	483.00K	450.00K
Total Liabilities	16.69M	13.80M	1.41M	3.88M	3.91M
Stockholders Equity	471.93M	382.22M	41.67M	51.04M	46.52M
Cash Flow
Free Cash Flow	-88.42M	-58.03M	-10.91M	-18.80M	-7.74M
Operating Cash Flow	-88.21M	-57.84M	-10.91M	-18.76M	-7.72M
Investing Cash Flow	-96.75M	-330.13M	-2.00K	-43.00K	-19.00K
Financing Cash Flow	170.31M	449.54M	0.00	23.09M	48.45M

Oruka Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 40.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORKA, the sentiment is Positive. The current price of 40.8 is above the 20-day moving average (MA) of 35.15, above the 50-day MA of 33.55, and above the 200-day MA of 23.52, indicating a bullish trend. The MACD of 1.79 indicates Negative momentum. The RSI at 66.46 is Neutral, neither overbought nor oversold. The STOCH value of 88.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORKA.

Oruka Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANAB	57 Neutral	$1.86B	-101.81	1813.84%	―	196.42%	53.92%
BCAX	56 Neutral	$1.17B	-5.93	-27.17%	―	―	-103.95%
ORKA	55 Neutral	$2.02B	-13.11	-23.05%	―	―	63.85%
CMPX	52 Neutral	$958.07M	-12.74	-43.61%	―	-100.00%	-28.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VSTM	49 Neutral	$488.36M	-2.55	-1849.88%	―	33.79%	-26.37%
OLMA	47 Neutral	$1.27B	―	-42.90%	―	―	17.23%